Table 3.

Survival analysis (Log-rank test) according to clinical-pathological factors in NSCLC Patients with BM

Variable	TKI group (N = 104)			Non-TKI group (N = 178)
	MOS	MPFSI	MPFSE	MOS	MPFSI	MPFSE
EGFR test (positive vs. negative)	NS	NS	S (P = 0.032)	NS	NS	NS
Age (<54years vs. ≥54years)	NS	NS	S (P = 0.014)	NS	NS	NS
Gender (female vs. male)	NS	NS	NS	NS	NS	NS
Smoking status (ever vs. never)	NS	NS	NS	NS	NS	NS
Histological type	NS	NS	NS	NS	NS	NS
Number of BM (cut off 3)	NS	NS	NS	S (P = 0.021)	NS	NS
Size of BM (cut off 3 cm)	NS	NS	NS	S (P = 0.012)	S (P = 0.025)	S (P = 0.032)
Treatment option (WBRT vs. S/SRS)	NS	NS	S (P = 0.011)	NS	NS	NS
Extracranial lesions (yes vs. no)	S (P = 0.0002)	NS	S (P = 0.013)	S (P = 0.003)	NS	NS
Intracranial symptoms (yes vs. no)	NS	NS	NS	NS	NS	NS
T staging (T ≤ 1 vs. T > 1)	NS	NS	S (P = 0.029)	S (P = 0.005)	NS	S (P = 0.007)
N staging (N0 vs N1 + 2 + 3)	S (P = 0.0003)	NS	S (P = 0.0005)	S (P = 0.0005)	S (P = 0.037)	NS
Adverse drug reaction (yes vs. no)	S (P = 0.0002)	NS	S (P = 0.0075)
TKI taking time (cut off 8 ms)	S (P < 0.0001)	S (P = 0.0006)	S (P = 0.0013)

MOS median overall survival, MPFSI median progression-free survival of intracranial disease, MPFSE median progression-free survival of extracranial disease, NS no significant, S significant